(CercleFinance.com) – Inventiva claims a cash position of 80.5 million euros as of March 31, 2022, compared to 95.4 million as of December 31, 2021, and specifies that it did not generate any turnover in the first quarter of 2022 , compared to 0.1 million euros a year earlier.
Given its current programs, the biopharmaceutical company confirms that its cash, cash equivalents and short-term deposits should allow it to finance its activities until the end of the first quarter of 2023.
In addition, Inventiva indicates that it now plans to finalize the recruitment of part 1 of the NATiV3 study with lanifibranor in NASH during the first half of 2023, instead of the second half of 2022 as previously announced.